NCT05435846View on ClinicalTrials.gov

Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation

PHASE1TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 10, 2022

Primary Completion Date

November 30, 2023

Study Completion Date

May 31, 2024

Conditions
Metastatic Lung Non-Small Cell CarcinomaStage IV Lung Cancer
Interventions
DRUG

Capmatinib

Given orally

DRUG

Trametinib

Given orally

Trial Locations (1)

94143

University of California San Francisco, San Francisco

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Collin Blakely

OTHER

NCT05435846 - Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation | Biotech Hunter | Biotech Hunter